Antisense Oligonucleotide (ASO) Therapeutics Market Report 2022-2032

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2022-2032

The Antisense Oligonucleotide Therapeutics (ASO) Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Tremendous Research Efforts to Drive Market Growth Further

Due to the absence of clinical efficacy even at large ASO doses, interest in antisense oligonucleotide-based medication discovery and development had previously declined. However, tremendous research efforts were undertaken at the chemistry and biology interface to enhance the biophysical and biological characteristics of the ASOs. Due to their improved in vivo efficacy and low off-target effects, several ASO-based medicines have received FDA and EMA approval. Medical and biological sciences are now more motivated than ever to use various classes of ASOs to cure uncommon and hereditary disorders that were previously thought to be untreatable by traditional small-molecule-based therapeutics. This is due to the discovery of new molecular targets. In order to expand their therapeutic application based on patient history and clinical outcome, various classes of ASOs are being successfully evaluated to treat the same diseases.

Several Potential Applications of ASO to Boost Market Growth

The present antisense drugs, which are still in the clinical development stage, specifically target certain tissues on a systemic and local level. The enhanced oligonucleotide chemistry increases the potency, safety, and tissue dispersion of the antisense drugs, further enhancing their properties. The mechanism of binding to RNA to decrease their activity both with & without RNA degradation has been improved by the development of oligonucleotide designs. Recent studies have shown that antisense oligonucleotides can also be used to either overexpress or decrease the creation of proteins. The effectiveness of new compounds in clinical trials will be the defining factor of how antisense technology is used in the future.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the antisense oligonucleotide therapeutics market evolving?
  • What is driving and restraining the antisense oligonucleotide therapeutics market?
  • How will each antisense oligonucleotide therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • How will the market shares for each antisense oligonucleotide therapeutics submarket develop from 2022 to 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading antisense oligonucleotide therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the antisense oligonucleotide therapeutics projects for these leading companies?
  • How will the industry evolve during the period between 2022 and 2032? What are the implications of
antisense oligonucleotide therapeutics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the antisense oligonucleotide therapeutics market?
  • Where is the antisense oligonucleotide therapeutics market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the antisense oligonucleotide therapeutics market today, and over the next 10 years:
  • Our 297-page report provides 117 tables and 152 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the antisense oligonucleotide therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Therapeutic Area
  • Genetic Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Metabolic Disorders
  • Ophthalmic Disorders
  • Others
Type
  • Ribozyme
  • DNAzyme
  • Anti-Gene
  • Other Types
Route of Administration
  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
  • U.S.
  • Canada
Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
MEA
  • GCC
  • South Africa
  • Rest of MEA
The report also includes profiles and for some of the leading companies in the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
  • Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Limited
  • Arrowhead Pharmaceuticals, Inc.
  • Biogen
  • Bio-Path Holdings
  • GSK
  • Geron Corporation (Geron)
  • Ionis Pharmaceuticals, Inc.
  • ProQR Therapeutics
  • Sarepta Therapeutics
  • Sterna Biologicals
Overall world revenue for Antisense Oligonucleotide Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$19 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032 report help you?

In summary, our 280+ page report provides you with the following knowledge:
  • Revenue forecasts to 2032 for Antisense Oligonucleotide Therapeutics Market, 2022 to 2032 Market, with forecasts for therapeutic area, type, and route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 11 of the major companies involved in the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.


1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antisense Oligonucleotide Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Worldwide Cancer Burden to Fuel Market Growth
3.2.1.2 Advances in Drug Delivery
3.2.2 Market Restraining Factors
3.2.2.1 Competition from Generics Likely to Hamper Market Growth
3.2.2.2 Distribution of Antisense Drugs to Distant Tumors
3.2.3 Market Opportunities
3.2.3.1 Investments by Major Players to Boost Market Growth
3.2.3.2 Emerging Markets
3.2.3.3 Development of Better Diagnostic Methods
3.2.3.4 Acquisitions and Partnerships
3.2.3.5 Pipeline Drugs Anticipated to Offer Lucrative Growth Opportunities
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Antisense Oligonucleotide Therapeutics Products and Technology Overview
4.1 Introduction to Nucleic Acid Technologies
4.2 Genetic Variation and Analysis
4.2.1 Sequencing Technologies
4.2.2 Sanger Sequencing
4.3 Next-generation Sequencing
4.3.1 DNA Write (Synthesis) Technologies
4.4 PCR-Based Approaches
4.5 Solid-Phase-Based Approaches
4.5.1 Microfluidic Technologies
4.5.2 DNA Microarrays
4.6 Gene Editing Technologies
4.7 CRISPR Enzyme Technologies
4.8 Gene Editing Delivery Technologies
4.9 Viral Delivery Technologies
4.9.1 Non-Viral Delivery Technologies
5 DNA Read, Write and Edit Initiatives
5.1 Initiatives
5.2 American Gut Consortium
5.2.1 BabySeq
5.2.2 Blood Profiling Atlas
5.2.3 Cancer-ID
5.2.4 Cancer Moon Shots Program
5.2.5 China Precision Medicine Initiative
5.2.6 Clinical Genome Resource
5.2.7 Epigenetics for Females Personalized Cancer Care
5.2.8 France Genomic Medicine Plan
5.2.9 Friends of Cancer Research Project
5.3 Gene Therapy Initiative
5.3.1 Immunomonitor Consortium
5.3.2 Integration of Imaging and Fluid-based Tumor Monitoring in Cancer Therapy Program
5.3.3 Laboratory for Genomics Research
5.3.4 Lung Cancer Master Protocol Project
5.3.5 Matchmaker Exchange
5.3.6 Medical Genome Initiative
5.3.7 Million Veteran Program
5.3.8 Molecular Integration in Neurological Diagnosis
5.3.9 MedSeq
5.4 National Microbiome Initiative
5.4.1 Next-generation Single Cell Analysis Program
5.4.2 Precision Medicine Initiative
5.4.3 Prospective Registry of Multiple Testing
5.4.4 Quality Assurance Initiative Pathology Project
5.4.5 Somatic Cell Genome Editing Program
5.4.6 Telomere-to-Telomere Consortium
5.4.7 Trans Omics for Precision Medicine Initiative
5.4.8 Population Sequencing Programs
6 Antisense Oligonucleotide Therapeutics Market Analysis by Therapeutic Area
6.1 Key Findings
6.2 Therapeutic Area Segment: Market Attractiveness Index
6.3 Antisense Oligonucleotide Therapeutics Market Size Estimation and Forecast by Therapeutic Area
6.4 Genetic Disorders
6.4.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Neurological Disorders
6.5.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Oncological Disorders
6.6.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.6.2 Market Share by Region, 2022 & 2032 (%)
6.7 Metabolic Disorders
6.7.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.7.2 Market Share by Region, 2022 & 2032 (%)
6.8 Ophthalmic Disorders
6.8.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.8.2 Market Share by Region, 2022 & 2032 (%)
6.9 Others
6.9.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.9.2 Market Share by Region, 2022 & 2032 (%)
7 Antisense Oligonucleotide Therapeutics Market Analysis by Type
7.1 Key Findings
7.2 Type Segment: Market Attractiveness Index
7.3 Antisense Oligonucleotide Therapeutics Market Size Estimation and Forecast by Type
7.4 Ribozyme
7.4.1 Market Forecast by Region, 2022-2032 (US$ bn)
7.4.2 Market Share by Region, 2022 & 2032 (%)
7.5 DNAzyme
7.5.1 Market Forecast by Region, 2022-2032 (US$ bn)
7.5.2 Market Share by Region, 2022 & 2032 (%)
7.6 Anti-Gene
7.6.1 Market Forecast by Region, 2022-2032 (US$ bn)
7.6.2 Market Share by Region, 2022 & 2032 (%)
7.7 Other Types
7.7.1 Market Forecast by Region, 2022-2032 (US$ bn)
7.7.2 Market Share by Region, 2022 & 2032 (%)
8 Antisense Oligonucleotide Therapeutics Market Analysis by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.3 Antisense Oligonucleotide Therapeutics Market Size Estimation and Forecast by Route of Administration
8.4 Pulmonary Delivery
8.4.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.4.2 Market Share by Region, 2022 & 2032 (%)
8.5 Intravenous Injections
8.5.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.5.2 Market Share by Region, 2022 & 2032 (%)
8.6 Intradermal Injections
8.6.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.6.2 Market Share by Region, 2022 & 2032 (%)
8.7 Intraperitoneal Injections
8.7.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.7.2 Market Share by Region, 2022 & 2032 (%)
8.8 Topical Delivery
8.8.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.8.2 Market Share by Region, 2022 & 2032 (%)
8.9 Others
8.9.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.9.2 Market Share by Region, 2022 & 2032 (%)
9 Antisense Oligonucleotide Therapeutics Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast
10 North America Antisense Oligonucleotide Therapeutics Market Analysis
10.1 Key Findings
10.2 North America Antisense Oligonucleotide Therapeutics Market Attractiveness Index
10.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
10.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
10.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
10.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
10.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
10.8 U.S.
10.9 Canada
11 Europe Antisense Oligonucleotide Therapeutics Market Analysis
11.1 Key Findings
11.2 Europe Antisense Oligonucleotide Therapeutics Market Attractiveness Index
11.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
11.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
11.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
11.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
11.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
11.8 Germany
11.9 UK
11.10 France
11.11 Italy
11.12 Spain
11.13 Rest of Europe
12 Asia Pacific Antisense Oligonucleotide Therapeutics Market Analysis
12.1 Key Findings
12.2 Asia Pacific Antisense Oligonucleotide Therapeutics Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
12.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
12.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
12.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
12.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
12.8 Japan
12.9 China
12.10 India
12.11 Australia
12.12 South Korea
12.13 Rest of Asia Pacific
13 Latin America Antisense Oligonucleotide Therapeutics Market Analysis
13.1 Key Findings
13.2 Latin America Antisense Oligonucleotide Therapeutics Market Attractiveness Index
13.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
13.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
13.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
13.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
13.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
13.8 Brazil
13.9 Mexico
13.10 Rest of Latin America
14 MEA Antisense Oligonucleotide Therapeutics Market Analysis
14.1 Key Findings
14.2 MEA Antisense Oligonucleotide Therapeutics Market Attractiveness Index
14.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
14.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
14.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
14.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
14.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
14.8 GCC
14.9 South Africa
14.10 Rest of MEA
15 Company Profiles
15.1 Biogen
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.3.1 Net Revenue, 2017-2021
15.1.3.2 Gross Profit, 2017-2021
15.1.3.3 R&D, 2017-2021
15.1.4 Product Benchmarking
15.1.5 Strategic Outlook
15.2 Bio-Path Holdings
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Product Benchmarking
15.2.4 Strategic Outlook
15.3 Ionis Pharmaceuticals, Inc.
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2017-2021
15.3.3.2 Gross Profit, 2017-2021
15.3.3.3 R&D, 2017-2021
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 ProQR Therapeutics
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Product Benchmarking
15.4.4 Strategic Outlook
15.5 Sarepta Therapeutics
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2017-2021
15.5.3.2 Gross Profit, 2017-2021
15.5.3.3 R&D, 2017-2021
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 Alnylam Pharmaceuticals, Inc.
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2017-2021
15.6.3.2 Gross Profit, 2017-2021
15.6.3.3 R&D, 2017-2021
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Arrowhead Pharmaceuticals, Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2017-2021
15.7.3.2 Gross Profit, 2017-2021
15.7.3.3 R&D, 2017-2021
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 GSK
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2017-2021
15.8.3.2 Gross Profit, 2017-2021
15.8.3.3 R&D, 2017-2021
15.8.4 Product Benchmarking
15.9 Geron Corporation (Geron)
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2017-2021
15.9.3.2 R&D, 2017-2021
15.9.4 Product Benchmarking
15.10 Antisense Therapeutics Limited
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2017-2021
15.10.3.2 R&D, 2017-2021
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
15.11 Sterna Biologicals
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Product Benchmarking
15.11.4 Strategic Outlook
16 Conclusion and Recommendations
16.1 Concluding Remarks from
16.2 Recommendations for Market Players

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings